New Zealand - engelsk - Medsafe (Medicines Safety Authority)

rex medical ltd - cyproterone acetate 2mg;  ;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg     ethinylestradiol 0.035mg   excipient: hypromellose lactose monohydrate magnesium stearate povidone propylene glycol purified talc   quinoline yellow starch titanium dioxide colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propylene glycol purified talc   starch titanium dioxide - androgen-dependent diseases in women are an indication for treatment with ginet. these diseases may include: acne (where local treatment or oral antibiotics alone have not been successful), especially pronounced forms of acne that may be accompanied by inflammation or formation of nodes (acne nodulocystica, acne papulopustulosa), seborrhea, mild forms of hirsutism and/or androgenic alopecia. oral contraception in women requiring treatment for these androgen-dependent diseases is an indication for treatment with ginet. however ginet is not recommended in women solely for contraception. it should not be used in combination with other hormonal contraceptives. ginet is indicated for the relief of symptoms of polycystic ovary syndrome.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 2mg;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg   ethinylestradiol 0.035mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry buff oy-3690 opadry white y-1r-7000b opaglos white 6000 povidone purified water quinoline yellow sucrose lactose monohydrate magnesium stearate microcrystalline cellulose - estelle-35 and estelle-35 ed are indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. estelle-35 and estelle-35 ed are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. estelle-35 and estelle-35 ed are also indicated for treating the symptoms of polycystic ovary syndrome.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

bayer new zealand limited - cyproterone acetate 2mg; ethinylestradiol 0.035mg - film coated tablet - active: cyproterone acetate 2mg ethinylestradiol 0.035mg excipient: calcium carbonate glycerol glycol montanate iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose titanium dioxide calcium carbonate glycol montanate lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone   purified talc   sucrose - · the treatment of signs of androgenisation in women, such as severe acne (involving inflammation or nodularity or risk of scarring) where prolonged oral antibiotics or local treatment alone has not been successful, or idiopathic hirsutism of mild to moderate degree.

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceres pharma sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - cyproterone acetate 2 mg; ethinylestradiol 35 µg - cyproterone and estrogen

Belgia - engelsk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ethinylestradiol 0,035 mg; cyproterone acetate 2 mg - coated tablet - 2 mg - 0,035 mg - ethinylestradiol 35 µg; cyproterone acetate 2 mg - cyproterone and estrogen

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cyproterone acetate 2mg;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg   ethinylestradiol 0.035mg   excipient: croscarmellose sodium opaglos 6000 white lactose monohydrate magnesium stearate microcrystalline cellulose opadry buff oy-3690 opadry white y-1r-7000b povidone purified water quinoline yellow sucrose - estelle-35 and estelle-35 ed are indicated for the treatment of androgen dependent diseases in women, such as acne (where oral antibiotics or local treatment alone has not been successful), especially pronounced forms and those which are accompanied by seborrhoea or by inflammation or formation of nodes (acne papulopustulosa, acne nodulocystica), androgenic alopecia, mild forms of hirsutism. estelle-35 and estelle-35 ed are also indicated for oral contraception in women requiring treatment for these androgen-dependent diseases; it is not recommended in women solely for contraception. estelle-35 and estelle-35 ed are also indicated for treating the symptoms of polycystic ovary syndrome.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

rex medical ltd - cyproterone acetate 2mg;  ;  ; ethinylestradiol 0.035mg;   - film coated tablet - active: cyproterone acetate 2mg     ethinylestradiol 0.035mg   excipient: hypromellose lactose monohydrate magnesium stearate povidone propylene glycol purified talc   quinoline yellow starch titanium dioxide - androgen-dependent diseases in women are an indication for treatment with ginet-63. these diseases may include: acne (where local treatment or oral antibiotics alone have not been successful), especially pronounced forms of acne that may be accompanied by inflammation or formation of nodes (acne nodulocystica, acne papulopustulosa), seborrhea, mild forms of hirsutism and/or androgenic alopecia. oral contraception in women requiring treatment for these androgen-dependent diseases is an indication for treatment with ginet-63. however ginet-63 is not recommended in women solely for contraception.